Supportive care and symptom management in patients with advanced hematological malignancies: a literature review

Abstract

Background and Objective: Recent advances have led to cure or long-term disease control for patients with hematological malignancy (HM). Unfortunately, some of them still have poor prognoses and are often associated with significant symptom burden and poor quality of life for patients and families. These patients usually require supportive care including red blood cell and platelet transfusion, due to disease itself and the oncological treatment, apart from their symptom management. However, there is currently lack of the literatures review in these aspects. The objective of this review is to summarize practical supportive care recommendations for physicians or nurses practicing in palliative care (PC)/hematology-oncology unit, starting with core approaches in use of blood products for anemia and thrombocytopenia, management of tumor lysis syndrome, PC and oncology nursing care. Methods: Evidence for this review was obtained from a search of the Cochrane database, PubMed, guidelines of European Society of Medical Oncology, British society of Hematology, American Society of Clinical Oncology, National Comprehensive Cancer Network and peer-reviewed journal articles. Key Content and Findings: For asymptomatic cancer patients who are anaemic, a threshold of haemoglobin level of 7 g/dL is considered to be safe and generally favored for blood transfusion. ‘Single-unit’ red cell transfusion is safer and at least as effective as ‘double-unit’ transfusion. Prophylactic platelet transfusion should be given to stable patients without bleeding and with platelet count less than 10×109/ L. In febrile patients, the threshold is lifted to 20×109 /L. There are also recommendations for the use of blood products during COVID-19 pandemic. In general, HM patients were more prone to painful infections when compared with solid cancer patients. Thus, antibiotics to treat underlying infections should be applied whenever possible and as required to control pain. Conclusions: This narrative review showed the recent literatures in the supportive care and symptom management of advanced HM patients. However, it is limited by some of the ‘ evidence-based’ recommendations for interventions (including symptom management) based on early phase of HM populations rather than those receiving end-of-life care.